Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
DrugBank Accession Number
DB15728
Background

Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties.

Once MSCs are isolated from the tissue through extraction procedures, they are cultured in the Dulbecco’s Modified Eagle’s Medium (DMEM) to separate soluble factors into the liquid.

Many companies are creating their own version of this medium. One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

The factors contained in the CM are thought to hold differentiation and therapeutic function, additionally, they may also intensify the positive effects of cell-based therapies. Some of the growth factors and cytokines found include IL-6, VEGF, angiogenin, and IGF-1. Through these factors, the conditioned medium exerts numerous effects, including accelerated wound healing, anti-photo aging, and induced differentiation.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Sriramulu S, Banerjee A, Di Liddo R, Jothimani G, Gopinath M, Murugesan R, Marotta F, Pathak S: Concise Review on Clinical Applications of Conditioned Medium Derived from Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs). Int J Hematol Oncol Stem Cell Res. 2018 Jul 1;12(3):230-234. [Article]
  2. Kim ES, Jeon HB, Lim H, Shin JH, Park SJ, Jo YK, Oh W, Yang YS, Cho DH, Kim JY: Conditioned Media from Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibits Melanogenesis by Promoting Proteasomal Degradation of MITF. PLoS One. 2015 May 29;10(5):e0128078. doi: 10.1371/journal.pone.0128078. eCollection 2015. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 19:06 / Updated on August 13, 2020 07:02